No. 20-1232

IBSA Institut Biochimique, S. A., et al. v. Teva Pharmaceuticals USA, Inc.

Lower Court: Federal Circuit
Docketed: 2021-03-08
Status: Denied
Type: Paid
Response Waived
Tags: foreign-inventors foreign-language indefiniteness national-treatment patent patent-indefiniteness patent-priority patent-prosecution priority-date trips-agreement
Latest Conference: 2021-04-01
Question Presented (from Petition)

Whether, pursuant to the United States' obligations under the TRIPS Agreement, codified at 19 U.S.C. § 3511, a court construing the claims of a U.S. patent may give no weight to a foreign priority patent application, despite its submission to the U.S. Patent & Trademark Office during prosecution of the patent-in-question, because it is written in a foreign language and exhibits minor differences from the U.S. patent resulting from a translator's judgment.

Question Presented (AI Summary)

Whether, pursuant to the United States' obligations under the TRIPS Agreement, codified at 19 U.S.C. § 3511, a court construing the claims of a U.S. patent may give no weight to a foreign priority patent application, despite its submission to the U.S. Patent & Trademark Office during prosecution of the patent-in-question, because it is written in a foreign language and exhibits minor differences from the U.S. patent resulting from a translator's judgment

Docket Entries

2021-04-05
Petition DENIED.
2021-03-16
DISTRIBUTED for Conference of 4/1/2021.
2021-03-10
Waiver of right of respondent Teva Pharmaceuticals USA, Inc. to respond filed.
2021-03-01
Petition for a writ of certiorari filed. (Response due April 7, 2021)

Attorneys

IBSA Institut Biochimique, S. A., et al., Altergon, S.A., IBSA Pharma Inc., Petitioners
Erica Ruth SutterFenwick & West LLP, Petitioner
IBSA Institut Biochimique, S.A, et al.
Jeffrey J. OelkeFenwick & West LLP, Petitioner
IBSA Istitut Biochimique, S.A., et al., Altergon, S.A., IBSA Pharma Inc., Petitioners
Laura Theresa MoranFenwick & West LLP, Petitioner
Teva Pharmaceuticals USA, Inc.
John Christopher RozendaalSTERNE, KESSLER, GOLDSTEIN & Fox P.L.L.C., Respondent